Petros Grivas, MD, shares his treatment plan for a patient with metastatic urothelial cancer who has progressed following platinum-based chemotherapy.

Margherita Rimini, MD, discusses the potential link between BRCAness phenotype and response to platinum-based chemotherapy in cholangiocarcinoma.

Ruth He, MD, discusses findings from a subgroup analysis assessing outcomes by primary tumor location in biliary tract cancer treated with durvalumab.

Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.

Robert Jones, MD, University of Glasgow, UK, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following chemotherapy for patients with metastatic urothelial carcinoma who were negative for DNA repair biomarkers

Petros Grivas, MD, from the University of Washington Fred Hutchinson Cancer Research Center, shares results from the TROPHY-U-01 phase 2 trial evaluating the use of sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.

Part 2: Overcoming PARP Inhibitor and Platinum Resistance in Patients With Ovarian Cancer by HMP Global

Stay tuned for Part 2!

Guenther Koehne, MD, PhD, interviews Richard Stone, MD; Robert Soiffer, MD; and Siddhartha Mukherjee, MD, on recent therapeutic advances for hematologic malignancies with a focus on considerations for treatment selection in high-risk AML.

Shenmiao Yang, MD, highlights a multicenter, phase 3 trial comparing ibrutinib versus rituximab for advanced CLL/SLL, in which ibrutinib outperformed rituximab in all therapy outcomes.